Boston Scientific BSX, a prominent global player in cardiovascular technology, is well-positioned to capitalize on the robust expansion of the cardiovascular devices market. According to a MarketsandMarkets report, this market was valued at $72.83 billion in 2023 and is expected to witness a strong CAGR of 7.3% between 2024 and 2029.
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Boston Scientific (BSX) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
In the most recent trading session, Boston Scientific (BSX) closed at $102.43, indicating a -0.65% shift from the previous trading day.
BSX posts solid Q1 sales growth in emerging markets, reinforcing their role in the company's long-term global strategy.
Boston Scientific is a global leader in medical devices, excelling in both MedSurg and Cardiovascular segments with consistent, industry-beating growth. Q1 2024 was a record quarter, with 21% YoY revenue growth, strong margins, and EPS beating expectations by $0.08. Organic growth and strategic acquisitions fuel BSX's expansion, supported by a diverse portfolio and active venture investments.
In the latest trading session, Boston Scientific (BSX) closed at $104.50, marking a -0.01% move from the previous day.
Boston Scientific Corporation (NYSE:BSX ) Bernstein 41st Annual Strategic Decisions Conference Call May 28, 2025 8:01 AM ET Company Participants Michael Mahoney - Chairman and Chief Executive Officer Kenneth Stein - Senior Vice President and Global Chief Medical Officer Conference Call Participants Lee Hambright - Sanford C. Bernstein & Co., LLC Lee Hambright Okay.
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?
Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and strategic acquisitions.
Boston Scientific Corporation (NYSE:BSX ) Bank of America's 2025 Health Care Conference May 13, 2025 11:00 AM ET Company Participants Daniel Brennan - EVP & CFO Joe Fitzgerald - EVP & Group President, Cardiology Conference Call Participants Travis Steed - Bank of America Travis Steed All right. Good morning, everybody.